专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

EP3543238B1 NUCLEOSIDE DERIVATIVES HAVING ANTI-VIRAL ACTIVITY 有权
公开(公告)号：EP3543238B1
公开(公告)日：2021-05-19
申请号：EP17871309.5
申请日：2017-11-13
发明人： MITSUYA Hiroaki , KUMAMOTO Hiroki
IPC分类号： C07D473/18 , A61P31/12 , A61P31/18 , A61P31/20 , A61K31/522 , A61K45/06

2. 发明公开

EP3725884A1 CELL-MEMBRANE-PERMEABLE PEPTIDE 审中-实审
公开(公告)号：EP3725884A1
公开(公告)日：2020-10-21
申请号：EP18889331.7
申请日：2018-12-10
申请人： Astellas Pharma Inc. , National Center for Global Health and Medicine , Hiroshima University
发明人： ENDO, Hideki , ISHIZAKA, Yukihito , ISHIGURO, Akira , TAKASHINA, Tomoki , YAMAMOTO, Takashi , SAKUMA, Tetsushi
IPC分类号： C12N15/13 , C07K7/06 , C07K14/00 , C12N15/62
摘要： An object of the present invention is to provide a cell penetrating peptide having a penetrating ability into cells.
The present inventors provided a cell penetrating peptide consisting of the amino acid sequence of SEQ ID NO: 1, a cell penetrating peptide consisting of the amino acid sequence of SEQ ID NO: 2 and a cell penetrating peptide consisting of the amino acid sequence of SEQ ID NO: 3; and a complex comprising any one of the cell penetrating peptide and a functional molecule.

3. 发明公开

EP3587560A1 ENDODERMAL CELL MASS, AND METHOD FOR PRODUCING ANY ONE OF THREE PRIMARY GERM LAYER CELL MASS FROM PLURIPOTENT CELLS 审中-公开
公开(公告)号：EP3587560A1
公开(公告)日：2020-01-01
申请号：EP18744653.9
申请日：2018-01-26
申请人： Kaneka Corporation , National Center for Global Health and Medicine
发明人： IBUKI Masato , OKOCHI Hitoshi , YABE Shigeharu
IPC分类号： C12N5/073 , C12N5/10
摘要： An object of the present invention is to provide an endodermal cell population for obtaining optimal somatic cells as cell therapy preparations. The endodermal cell population of the present invention has a reduced content proportion of undifferentiated cells in the cell population and contains endodermal cells differentiable into optimal somatic cells as cell therapy preparations. Further, a somatic cell derived from the endodermal cell population of the present invention has excellent therapeutic effects as a cell therapy preparation.

4. 发明授权

EP2703481B1 PLURIPOTENT STEM CELL-DERIVED BROWN ADIPOCYTES, PLURIPOTENT STEM CELL-DERIVED CELL AGGREGATE, METHOD FOR PRODUCING SAME, AND CELL THERAPY AND MEDICAL THERAPY THEREFOR 有权转让
公开(公告)号：EP2703481B1
公开(公告)日：2018-11-14
申请号：EP12776134.4
申请日：2012-04-26
申请人： National Center for Global Health and Medicine , ID Pharma Co., Ltd.
发明人： SAEKI, Kumiko , YUO, Akira , NISHIO, Miwako , KAWASAKI, Masako , SAEKI, Koichi , HASEGAWA, Mamoru
IPC分类号： C12N5/077 , A61K35/35
CPC分类号： A61K35/35 , A61K35/28 , C12N5/0653 , C12N2501/105 , C12N2501/155 , C12N2501/165 , C12N2501/2306 , C12N2501/26 , C12N2506/45
摘要： Provided are a method of producing brown adipocytes from pluripotent stem cells, a method of producing cell aggregates as an intermediate product thereof, pluripotent stem cell-derived cell aggregates and pluripotent stem cell-derived brown adipocytes produced by these methods, and cell therapy using the pluripotent stem cell-derived brown adipocytes. In the method of producing brown adipocytes from pluripotent stem cells, cell aggregates are produced from pluripotent stem cells by a method including the step (A), and brown adipocytes are prepared from the cell aggregates by a method including the step (B). The step (A) is a step of producing cell aggregates by non-adhesive culture of pluripotent stem cells in serum-free environment in the presence of a hematopoietic cytokine, and the step (B) is a step of producing brown adipocytes by adhesion culture of the cell aggregates in the presence of a hematopoietic cytokine.

5. 发明授权

EP2846162B1 Method for measuring glycoprotein and reagent for quantitative determination of glycoprotein 有权
公开(公告)号：EP2846162B1
公开(公告)日：2018-09-05
申请号：EP14187288.7
申请日：2010-07-14
申请人： National Institute of Advanced Industrial Science and Technology , Nagoya City University , National Center for Global Health and Medicine , SYSMEX CORPORATION
发明人： Narimatsu, Hisashi , Ikehara, Yuzuru , Kuno, Atsushi , Sogabe, Maki , Tanaka, Yasuhito , Mizokami, Masashi , Ito, Kiyoaki , Matsubara, Shunsuke , Tsuruno, Chikayuki , Takahama, Youichi , Kagawa, Takashi , Nagai, Shinya
IPC分类号： G01N33/53
CPC分类号： G01N33/68 , C07K14/4726 , C07K14/473 , G01N33/5308 , G01N33/57438 , G01N33/6893 , G01N2333/4724 , G01N2333/4728 , G01N2400/00 , G01N2400/02 , G01N2800/085 , Y10T436/143333
摘要： An object of the present invention is to provide a method for measuring a glycan-marker glycoprotein, by which liver disease can be detected with higher accuracy than is possible with conventional methods. Also, an object of the present invention is to provide a method for examining liver disease, by which liver disease can be detected with higher accuracy than is possible with conventional methods. Also, an object of the present invention is to provide a reagent for quantitative determination of a glycoprotein, which is used for the above measurement methods. Furthermore, an object of the present invention is to provide a glycan-marker glycoprotein as an index for clinical conditions of liver disease, which is capable of identifying the clinical conditions of liver disease depending on the progress of liver disease. The method for measuring a glycoprotein is characterized in that : the glycoprotein is at least one glycoprotein selected from alpha-1-acid glycoprotein (AGP) and Mac-2-binding protein (M2BP) contained in a sample collected from a subject; when the glycoprotein is AGP, AGP binding to a first lectin selected from AOL and MAL is measured; and when the glycoprotein is M2BP, M2BP binding to a second lectin selected from WFA, BPL, AAL, RCA120, and TJAII is measured.

6. 发明公开

EP3040422A1 METHOD FOR DETECTING PREDISPOSITION FOR HEPATITIS B TO BECOME CHRONIC 审中-公开
标题翻译： VERFAHREN ZUM NACHWEIS EINERPRÄDISPOSITIONFÜRCHRONISCHE HEPATITIS B
公开(公告)号：EP3040422A1
公开(公告)日：2016-07-06
申请号：EP14841107.7
申请日：2014-08-28
申请人： The University of Tokyo , National Center for Global Health and Medicine
发明人： TOKUNAGA Katsushi , SAWAI Hiromi , MIZOKAMI Masashi , NISHIDA Nao
IPC分类号： C12Q1/68 , C12N15/09
CPC分类号： C12Q1/706 , C12Q2600/118 , C12Q2600/156 , C12Q2600/172
摘要： An object of the present invention is to provide a method for detecting predisposition for chronicity of hepatitis B and/or the pathological progress, including an allele associated with chronicity of hepatitis B and/or the pathological progress. The above-described object is achieved by providing a method that includes a process of identifying alleles which are susceptible and resistant to chronicity of hepatitis B and/or the pathological progress in which a difference between a chronic hepatitis B patient group and a healthy control group is accurately reflected and comparing the alleles with base sequences or amino acid sequences corresponding to the alleles in a specimen; a process of analyzing whether bases of sites corresponding to the alleles in the base sequences of the specimen match bases of the alleles; and a process of specifying whether the hepatitis B of the specimen becomes chronic and/or the pathology is progressed, a method of performing inspection using the method, a reagent used for the method, and a test kit including the reagent.
摘要翻译：本发明的目的是提供一种用于检测乙型肝炎长期性倾向和/或病理进展的方法，包括与乙型肝炎的慢性相关的等位基因和/或病理进展。上述目的通过提供一种方法来实现，该方法包括鉴定易感和耐乙型肝炎慢性的等位基因的过程和/或慢性乙型肝炎患者组与健康对照组之间的差异的病理进展准确反映和比较等位基因与对应于样品中的等位基因的碱基序列或氨基酸序列; 分析与样本的碱基序列中的等位基因相对应的位点的碱基是否与等位基因的碱基相匹配的过程; 以及确定样本的乙型肝炎是否变得慢性和病变进行的方法，使用该方法进行检查的方法，用于该方法的试剂以及包含该试剂的试剂盒的处理。

7. 发明公开

EP2950098A1 GLYCAN MARKERS AS MEASURE OF DISEASE STATE OF HEPATIC DISEASES 审中-公开
标题翻译： GLYCAN-MARKER ALS MASS EINES KRANKHEITSZUSTANDS VON LEBERERKRANKUNGEN
公开(公告)号：EP2950098A1
公开(公告)日：2015-12-02
申请号：EP15174779.7
申请日：2010-07-12
申请人： National Institute of Advanced Industrial Science and Technology , Nagoya City University , National Center for Global Health and Medicine
发明人： Narimatsu, Hisashi , Hirabayashi, Jun , Ikehara, Yuzuru , Angata, Takashi , Kaji, Hiroyuki , Kuno, Atsushi , Ohkura, Takashi , Shikanai, Toshihide , Sogabe, Maki , Togayachi, Akira , Ochou, Makoto , Tanaka, Yasuhito , Mizokami, Masashi
IPC分类号： G01N33/574 , C07K9/00 , C07K14/47
CPC分类号： C07K9/00 , C07K14/47 , G01N33/57438 , G01N33/57469 , G01N2400/02 , G01N2800/085
摘要： The present invention is directed to developing a glycan markers capable of detecting a hepatic disease, and more specifically to developing a glycan marker indicating a hepatic disease-state. Furthermore, the present invention is also directed to developing a glycan marker capable of distinguishing hepatic disease-states with the progress of hepatocarcinoma. The present inventors identified, among the serum glycoproteins, glycopeptides and glycoproteins in which a glycan structure specifically changes due to a hepatic disease including hepatocarcinoma and provide these as novel glycan markers (glycopeptide and glycoprotein) specific to hepatic disease-states.
摘要翻译：本发明涉及开发能够检测肝脏疾病的聚糖标记物，更具体地说，涉及发展表达肝病状态的聚糖标记物。此外，本发明还涉及开发能够区分肝脏疾病状态与肝癌进展的聚糖标记物。本发明人鉴定了血清糖蛋白中由于包括肝癌在内的肝脏疾病而特异性地改变聚糖结构的糖肽和糖蛋白，并且将它们提供为肝脏疾病状态特异性的新型聚糖标记（糖肽和糖蛋白）。

8. 发明公开

EP2455389A1 SUGAR CHAIN MARKER AS MEASURE OF DISEASE CONDITIONS OF HEPATIC DISEASES 审中-公开
标题翻译：糖链标志物为基准的肝病疾病阶段
公开(公告)号：EP2455389A1
公开(公告)日：2012-05-23
申请号：EP10799822.1
申请日：2010-07-12
申请人： National Institute of Advanced Industrial Science and Technology , Nagoya City University , National Center for Global Health and Medicine
发明人： NARIMATSU, Hisashi , HIRABAYASHI, Jun , IKEHARA, Yuzuru , ANGATA, Takashi , KAJI, Hiroyuki , KUNO, Atsushi , OOKURA, Takashi , SHIKANAI, Toshihide , SOGABE, Maki , TOGAYACHI, Akira , OCHOU, Makoto , TANAKA Yasuhito , MIZOKAMI Masashi
IPC分类号： C07K9/00 , C07K14/47 , G01N33/53
CPC分类号： C07K9/00 , C07K14/47 , G01N33/57438 , G01N33/57469 , G01N2400/02 , G01N2800/085
摘要： The present invention is directed to developing a glycan markers capable of detecting a hepatic disease, and more specifically to developing a glycan marker indicating a hepatic disease-state. Furthermore, the present invention is also directed to developing a glycan marker capable of distinguishing hepatic disease-states with the progress of hepatocarcinoma. The present inventors identified, among the serum glycoproteins, glycopeptides and glycoproteins in which a glycan structure specifically changes due to a hepatic diseases including hepatocarcinoma and provide these as novel glycan markers (glycopeptide and glycoprotein) specific to hepatic disease-states.

9. 发明公开

EP2703481A4 PLURIPOTENT STEM CELL-DERIVED BROWN ADIPOCYTES, PLURIPOTENT STEM CELL-DERIVED CELL AGGREGATE, METHOD FOR PRODUCING SAME, AND CELL THERAPY AND MEDICAL THERAPY THEREFOR 有权转让
标题翻译：关多能干WON褐色脂肪细胞OFF多能干获得的细胞单元，加工用于生产和细胞治疗和医学治疗中的
公开(公告)号：EP2703481A4
公开(公告)日：2014-11-12
申请号：EP12776134
申请日：2012-04-26
申请人： NAT CT FOR GLOBAL HEALTH & MEDICINE , DNAVEC CORP
发明人： SAEKI KUMIKO , YUO AKIRA , NISHIO MIWAKO , KAWASAKI MASAKO , SAEKI KOICHI , HASEGAWA MAMORU
IPC分类号： C12N5/077 , A61K35/12 , A61L27/00 , A61P3/06 , A61P3/10 , A61P9/10 , C12N5/10 , C12N15/09
CPC分类号： A61K35/35 , A61K35/28 , C12N5/0653 , C12N2501/105 , C12N2501/155 , C12N2501/165 , C12N2501/2306 , C12N2501/26 , C12N2506/45
摘要： Provided are a method of producing brown adipocytes from pluripotent stem cells, a method of producing cell aggregates as an intermediate product thereof, pluripotent stem cell-derived cell aggregates and pluripotent stem cell-derived brown adipocytes produced by these methods, and cell therapy using the pluripotent stem cell-derived brown adipocytes. In the method of producing brown adipocytes from pluripotent stem cells, cell aggregates are produced from pluripotent stem cells by a method including the step (A), and brown adipocytes are prepared from the cell aggregates by a method including the step (B). The step (A) is a step of producing cell aggregates by non-adhesive culture of pluripotent stem cells in serum-free environment in the presence of a hematopoietic cytokine, and the step (B) is a step of producing brown adipocytes by adhesion culture of the cell aggregates in the presence of a hematopoietic cytokine.

10. 发明公开

EP2322659A1 METHOD AND SPECIMEN FOR DETECTING SENSITIVITY TO ISONIAZID IN TUBERCLE BACILLUS 有权
标题翻译： VERFAHREN ZUM NACHWEIS DER EMPFINDLICHKEITGEGENÜBERISONIAZID BEI M. TUBERCULOSIS
公开(公告)号：EP2322659A1
公开(公告)日：2011-05-18
申请号：EP09773502.1
申请日：2009-07-01
申请人： NIPRO CORPORATION , National Center for Global Health and Medicine
发明人： KIRIKAE, Teruo , ANDOU, Hiroki , SUETAKE, Toshinori , NAKAMURA, Tomohiko
IPC分类号： C12Q1/68 , C12N15/09 , G01N33/53 , G01N37/00
CPC分类号： C12Q1/689 , C12Q2600/156 , G01N33/5695 , G01N2333/35 , G01N2800/44
摘要： According to the present invention, novel means for more reliably detecting sensitivity to INH in Mycobacterium tuberculosis, that is, detecting whether or not M . tuberculosis is an INH-resistant bacterium is provided. A method for detecting sensitivity to Isoniazid in M . tuberculosis, comprising the steps of obtaining a fabG1 gene of M . tuberculosis in a sample; and detecting a mutation involved in resistance to Isoniazid with respect to the obtained fabG1 gene. The method of the invention may, if necessary, comprise a step of detecting a mutation in a furA gene of M . tuberculosis, and may preferably be combined with another known method for detecting sensitivity to Isoniazid.
摘要翻译：根据本发明，用于更可靠地检测结核分枝杆菌INH敏感性的新方法，即是否检测M。提供结核病是一种INH抗性细菌。一种用于检测M中异烟肼敏感性的方法。结核病，包括获得M的fabG1基因的步骤。样本中的结核病; 并检测相对于获得的fabG1基因涉及对异烟肼的抗性的突变。如果需要，本发明的方法可以包括检测M的furA基因突变的步骤。并且可以优选与用于检测对异烟肼敏感性的另一已知方法组合。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式